These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35047421)

  • 61. Dysregulation of Escherichia coli α-hemolysin expression alters the course of acute and persistent urinary tract infection.
    Nagamatsu K; Hannan TJ; Guest RL; Kostakioti M; Hadjifrangiskou M; Binkley J; Dodson K; Raivio TL; Hultgren SJ
    Proc Natl Acad Sci U S A; 2015 Feb; 112(8):E871-80. PubMed ID: 25675528
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Escherichia coli B2 Phylogenetic Subgroups in the Infant Gut Microbiota: Predominance of Uropathogenic Lineages in Swedish Infants and Enteropathogenic Lineages in Pakistani Infants.
    Nowrouzian FL; Clermont O; Edin M; Östblom A; Denamur E; Wold AE; Adlerberth I
    Appl Environ Microbiol; 2019 Dec; 85(24):. PubMed ID: 31562173
    [No Abstract]   [Full Text] [Related]  

  • 63. Indwelling Urinary Catheter Model of Proteus mirabilis Infection.
    Smith SN; Armbruster CE
    Methods Mol Biol; 2019; 2021():187-200. PubMed ID: 31309506
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli.
    Asadi Karam MR; Habibi M; Bouzari S
    Mol Immunol; 2019 Apr; 108():56-67. PubMed ID: 30784763
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Presence of putative repeat-in-toxin gene tosA in Escherichia coli predicts successful colonization of the urinary tract.
    Vigil PD; Stapleton AE; Johnson JR; Hooton TM; Hodges AP; He Y; Mobley HL
    mBio; 2011; 2(3):e00066-11. PubMed ID: 21540363
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Analysis of inflammatory cytokine expression in the urinary tract of BALB/c mice infected with Proteus (P.) mirabilis and enteroaggregative Escherichia (E.) coli (EAEC) strains.
    Melendez-Avalos A; Sainz-Espuñes T; Castrillón-Rivera LE; Mendoza-Pérez F; Palma-Ramos A; Castañeda-Sánchez JI; Drago-Serrano EM
    Folia Microbiol (Praha); 2020 Feb; 65(1):133-142. PubMed ID: 31104302
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Recurrent Urinary Tract Infection: A Mystery in Search of Better Model Systems.
    Murray BO; Flores C; Williams C; Flusberg DA; Marr EE; Kwiatkowska KM; Charest JL; Isenberg BC; Rohn JL
    Front Cell Infect Microbiol; 2021; 11():691210. PubMed ID: 34123879
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reaching the End of the Line: Urinary Tract Infections.
    Tamadonfar KO; Omattage NS; Spaulding CN; Hultgren SJ
    Microbiol Spectr; 2019 May; 7(3):. PubMed ID: 31172909
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The human gut microbe
    Ndeh D; Munoz Munoz J; Cartmell A; Bulmer D; Wills C; Henrissat B; Gray J
    J Biol Chem; 2018 Nov; 293(46):17906-17916. PubMed ID: 30262663
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Metabolism and Fitness of Urinary Tract Pathogens.
    Alteri CJ; Mobley HLT
    Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185076
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Virulence factors of uropathogenic E. coli and their interaction with the host.
    Lüthje P; Brauner A
    Adv Microb Physiol; 2014; 65():337-72. PubMed ID: 25476769
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Establishment and Characterization of UTI and CAUTI in a Mouse Model.
    Conover MS; Flores-Mireles AL; Hibbing ME; Dodson K; Hultgren SJ
    J Vis Exp; 2015 Jun; (100):e52892. PubMed ID: 26132341
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Urinary tract infections, immunity, and vaccination].
    Luna-Pineda VM; Ochoa S; Cruz-Córdova A; Cázares-Domínguez V; Vélez-González F; Hernández-Castro R; Xicohtencatl-Cortes J
    Bol Med Hosp Infant Mex; 2018; 75(2):67-78. PubMed ID: 29658949
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intramacrophage survival of uropathogenic Escherichia coli: differences between diverse clinical isolates and between mouse and human macrophages.
    Bokil NJ; Totsika M; Carey AJ; Stacey KJ; Hancock V; Saunders BM; Ravasi T; Ulett GC; Schembri MA; Sweet MJ
    Immunobiology; 2011 Nov; 216(11):1164-71. PubMed ID: 21802164
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Defining a Molecular Signature for Uropathogenic versus Urocolonizing Escherichia coli: The Status of the Field and New Clinical Opportunities.
    Eberly AR; Beebout CJ; Carmen Tong CM; Van Horn GT; Green HD; Fitzgerald MJ; De S; Apple EK; Schrimpe-Rutledge AC; Codreanu SG; Sherrod SD; McLean JA; Clayton DB; Stratton CW; Schmitz JE; Hadjifrangiskou M
    J Mol Biol; 2020 Feb; 432(4):786-804. PubMed ID: 31794727
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Genome-wide mapping of cystitis due to Streptococcus agalactiae and Escherichia coli in mice identifies a unique bladder transcriptome that signifies pathogen-specific antimicrobial defense against urinary tract infection.
    Tan CK; Carey AJ; Cui X; Webb RI; Ipe D; Crowley M; Cripps AW; Benjamin WH; Ulett KB; Schembri MA; Ulett GC
    Infect Immun; 2012 Sep; 80(9):3145-60. PubMed ID: 22733575
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bacterial Microcompartment-Mediated Ethanolamine Metabolism in Escherichia coli Urinary Tract Infection.
    Dadswell K; Creagh S; McCullagh E; Liang M; Brown IR; Warren MJ; McNally A; MacSharry J; Prentice MB
    Infect Immun; 2019 Aug; 87(8):. PubMed ID: 31138611
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Characterization of Escherichia coli isolates from hospital inpatients or outpatients with urinary tract infection.
    Toval F; Köhler CD; Vogel U; Wagenlehner F; Mellmann A; Fruth A; Schmidt MA; Karch H; Bielaszewska M; Dobrindt U
    J Clin Microbiol; 2014 Feb; 52(2):407-18. PubMed ID: 24478469
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Genome-wide transposon mutagenesis of Proteus mirabilis: Essential genes, fitness factors for catheter-associated urinary tract infection, and the impact of polymicrobial infection on fitness requirements.
    Armbruster CE; Forsyth-DeOrnellas V; Johnson AO; Smith SN; Zhao L; Wu W; Mobley HLT
    PLoS Pathog; 2017 Jun; 13(6):e1006434. PubMed ID: 28614382
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Oral supplementation of trans-cinnamaldehyde reduces uropathogenic Escherichia coli colonization in a mouse model.
    Narayanan A; Muyyarikkandy MS; Mooyottu S; Venkitanarayanan K; Amalaradjou MA
    Lett Appl Microbiol; 2017 Mar; 64(3):192-197. PubMed ID: 28063174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.